Ozcan ORSCELİK, Bugra OZKAN, Mert Koray OZCAN

The contribution of implantable cardioverter defibrillators to systemic inflammation in heart failure patients

Heart failure (HF) is associated with an increased ‘inflammatory burden’, which is manifested by the elevation of serum levels of some inflammatory mediators such C-reactive protein (CRP), cytokines. In addition, high levels of inflammatory markers in patients with HF have been associated with poor outcomes. Lethal ventricular arrhythmias such as asystole and ventricular fibrillation-tachycardia are common in patients with HF and implantable cardioverter defibrillators (ICDs) are effective in preventing these situations. But like every foreign object in the body, ICDs also cause fibrosis and inflammation. This study aimed to show additional contribution of ICDs to systemic inflammation in patients with HF. This is a single centrer retrospective study included 140 HF patients with and without ICD (group 1 and 2) and 53 healty control subjects (group 3). Three groups were compared with regard to Hs-CRP and Neutrophil / Lymphocyte ratio (NL ratio). In order that acute inflammation did not affect the results, the earliest 6th month laboratory measures after ICD implantation were recorded. There are not significant difference between all groups in terms of age and gender, and among group 1 and 2 in terms of disease history, ejection fraction, heart rate and creatinine. When compared to the three groups according to Hs-CRP and NL ratio, there was a significant difference between the groups (both p

PDF

___

Orscelik O, Ozkan B, Arslan A, et al. Relationship between intrarenal reninangiotensin activity and re-hospitalization in patients with heart failure with reduced ejection fraction. Anatol J Cardiol. 2018;19:205-12.

Lappegard KT, Bjornstad H, Mollnes TE, et al. Effect of Cardiac resynchronization therapy on inflammation in congestive heart failure: A review. Scand J Immunol. 2015;82:191-8.

Kocyigit I, Eroglu E, Unal A, et al. Role of neutrophil/lymphocyte ratio in prediction of disease progression in patients with stage-4 chronic kidney disease. J Nephrol. 2013;26:358-65.

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-200.

Candinas R, Duru F, Schneider J, et al. Postmortem analysis of encapsulation around long-term ventricular endocardial pacing leads. Mayo Clin Proc. 1999;74:120-5.

Tompkins C, Cheng A, Brinker JA, et al. Significance of leukocytosis after cardiac device implantation. Am J Cardiol. 2013;111:1608-12.

Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol. 2013;62:147-239.

Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481-8.

Brancati FL, Whittle JC, Whelton PK, et al. The excess incidence of diabetic end-stage renal disease among blacks. A population-based study of potential explanatory factors. JAMA. 1992;268:3079-84.

Rudiger A, Burckhardt OA, Harpes P, et al. The relative lymphocyte count on hospital admission is a risk factor for long-term mortality in patients with acute heart failure. Am J Emerg Med. 2006;24:451-4.

Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22):2243-51, 4p following 51.

Verma A, Lavie CJ, Milani RV. C-Reactive Protein: How Has JUPITER Impacted Clinical Practice? Ochsner J. 2009;9:204-10.

Norata GD, Marchesi P, Pulakazhi Venu VK, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009;120:699-708.

Wojciechowska C, Romuk E, Tomasik A, et al. Oxidative stress markers and C-reactive protein are related to severity of heart failure in patients with dilated cardiomyopathy. Mediators Inflamm. 2014;2014:147040.

Pye M, Rae AP, Cobbe SM. Study of serum C-reactive protein concentration in cardiac failure. Br Heart J. 1990;63:228-30.

Sato Y, Takatsu Y, Kataoka K, et al. Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol. 1999;22:811-3.

Cevik C, Perez-Verdia A, Nugent K. Implantable cardioverter defibrillators and their role in heart failure progression. Europace. 2009;11:710-5.

Stumpf C, Sheriff A, Zimmermann S, et al. C-reactive protein levels predict systolic heart failure and outcome in patients with first ST-elevation myocardial infarction treated with coronary angioplasty. Arch Med Sci. 2017;13:1086-93.

Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol. 2008;52:501-11.

Vazir A, Claggett B, Jhund P, et al. Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. Eur Heart J. 2015;36:669-75.